MUIR Study Results: Plozasiran, an investigational RNAi therapeutic, silences apolipoprotein C3, and reduces atherosclerosis associated lipoproteins in patients with mixed hyperlipidemia
Please note:
This action will also remove this member from your connections and send a report to the site admin.
Please allow a few minutes for this process to complete.